STOCK TITAN
  1. Home
  2. NK

NK (NK) Stock Price, News & Analysis

NK

Company Description

This page collects what Stock Titan holds for NK, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart
$—
0.00%
0.00
Last updated:
-
Performance 1 year
$0.0
Market Cap
0.0
Shares outstanding

Latest News

View All
—

ImmunityBio and NantKwest Complete Merger

acquisition
+14.89%

Stockholders of NantKwest Approve Merger With ImmunityBio

acquisition
+5.52%

ImmunityBio and NantKwest Begin Dosing Participants in Global Trials for Novel COVID-19 Vaccine; Subcutaneous Route in South Africa, Oral and Sublingual in the U.S.

covid-19
+0.83%

ImmunityBio Appoints John Brennan and Wesley Clark to Board of Directors

management
+8.28%

ImmunityBio Announces ASCO Genitourinary Cancer Symposium Presentation of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate

clinical trial
+18.74%

ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal, and Antibody Immunity

fda approval covid-19

NK has 10 recent news articles. Of the recent coverage, 7 articles coincided with positive price movement and 2 with negative movement. Key topics include acquisition, covid-19, management, clinical trial, fda approval. View all NK news →

SEC Filings

View All

No SEC filings available for NK.

Financial Highlights

—
Revenue (latest FY)
—
Net Income (latest FY)
—
Diluted EPS (latest FY)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months